ストックスクリーナーアプリを入手
1.54
1.99%
0.03
前日終値:
$1.51
開ける：
$1.49
24時間の取引高:
67,845
Relative Volume:
0.08
時価総額：
$75.69M
収益：
$134.60K
当期純損益:
$-11.81M
株価収益率:
-6.3927
EPS:
-0.2409
ネットキャッシュフロー:
$-10.05M
1週間 パフォーマンス:
-1.28%
1か月 パフォーマンス:
-1.91%
6か月 パフォーマンス:
+11.59%
1年 パフォーマンス:
-28.04%
1日の値動き範囲:
$1.48
$1.545
1週間の範囲:
$1.48
$1.58
52週間の値動き範囲:
$1.13
$2.2364
Medicinova Inc Stock (MNOV) Company Profile
MNOV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.54 | 74.21M | 134.60K | -11.81M | -10.05M | -0.2409 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-03-10 | 開始されました | Maxim Group | Buy |
| 2019-03-25 | 再開されました | B. Riley FBR | Buy |
| 2018-03-28 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | 開始されました | Credit Suisse | Outperform |
| 2013-01-04 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2012-05-24 | ダウングレード | MLV & Co | Buy → Hold |
| 2011-10-18 | 繰り返されました | MLV Capital | Buy |
| 2011-06-22 | 開始されました | Global Hunter Securities | Buy |
| 2010-05-12 | 開始されました | Wedbush | Outperform |
| 2008-11-12 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2008-05-15 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | 開始されました | Punk, Ziegel & Co | Buy |
すべてを表示
Medicinova Inc (MNOV) 最新ニュース
MediciNova (NASDAQ:MNOV) Receives “Buy” Rating from D. Boral Capital - Defense World
MediciNova (MNOV) Analyst Rating Maintained at 'Buy' with $9.00 - GuruFocus
D. Boral Capital Maintains MediciNova (MNOV) Buy Recommendation - Nasdaq
MediciNova completes enrollment in phase 2b/3 ALS clinical trial - Investing.com
MediciNova Provides Update on COMBAT-ALS Study of MN-166 for Amyotrophic Lateral Sclerosis - Quiver Quantitative
MediciNova (NASDAQ: MNOV) fully enrolls 234-patient Phase 2b/3 ALS ALS trial, targets 2026 top-line data - Stock Titan
Is MediciNova Inc a good long term investmentTake Profit Strategies & Ride the Wave of Market-Beating Growth - earlytimes.in
Gainers Report: Can MediciNova Inc stock continue upward trendShare Buyback & Growth Focused Investment Plans - BỘ NỘI VỤ
Can MediciNova Inc. stock sustain free cash flow growthMarket Volume Report & Free Weekly Chart Analysis and Trade Guides - Newser
EBITDA per share of MediciNova, Inc. – TSE:4875 - TradingView
Can MediciNova Inc. stock continue upward trendJuly 2025 Price Swings & Verified Entry Point Signals - Newser
MediciNova (MNOV) Stock Analysis Report | Financials & Insights - Benzinga
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
MediciNova, Inc. (MNOV) 9.22% in After-hours: Amid Routine Trading - Stocks Telegraph
MediciNova Reports Significant Milestone in MN-001 Program Following Journal Publication on Cholesterol Efflux Mechanism - Quiver Quantitative
Message from the CEO to MediciNova Shareholders - GlobeNewswire
MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’ - MSN
Stocks of Medicinova Inc (MNOV) are poised to climb above their peers - Setenews
Is MediciNova Inc. stock attractive for growth ETFsPortfolio Gains Summary & Risk Controlled Swing Alerts - BỘ NỘI VỤ
Why MediciNova Inc. stock could benefit from AI revolutionWeekly Gains Summary & Entry Point Strategy Guides - moha.gov.vn
Market Moves: Why MediciNova Inc. stock could benefit from AI revolutionAnalyst Downgrade & Verified Entry Point Signals - BỘ NỘI VỤ
MediciNova (NASDAQ:MNOV) Stock Price Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Can MediciNova Inc. stock attract ESG capital inflowsPortfolio Return Summary & Weekly Stock Breakout Alerts - newser.com
Can MediciNova Inc. stock beat market expectations this quarterCPI Data & Weekly Breakout Stock Alerts - newser.com
Will MediciNova Inc. stock continue upward momentumJuly 2025 Gainers & Weekly Breakout Opportunity Watchlist - newser.com
Trend analysis for MediciNova Inc. this weekJuly 2025 Breakouts & AI Driven Stock Price Forecasts - newser.com
Will MediciNova Inc. stock maintain growth story2025 Top Decliners & Daily Profit Focused Screening - newser.com
What Fibonacci levels say about MediciNova Inc. reboundWeekly Trade Summary & Real-Time Sentiment Analysis - newser.com
What dividend safety score for MediciNova Inc. stockShort Setup & Real-Time Chart Breakout Alerts - newser.com
Is MediciNova Inc. stock a contrarian buy2025 Big Picture & Precise Entry and Exit Recommendations - newser.com
Applying big data sentiment scoring on MediciNova Inc.2025 Key Highlights & Smart Swing Trading Alerts - newser.com
MediciNova appoints former FDA official as clinical advisor By Investing.com - Investing.com Nigeria
MediciNova appoints former FDA official as clinical advisor - Investing.com
MediciNova, Inc. Appoints Dr. Christopher D. Breder as Clinical and Regulatory Advisor - Quiver Quantitative
Medicinova Inc (MNOV) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):